Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Oct;6(5):534-43.
doi: 10.3978/j.issn.2078-6891.2015.047.

Neoadjuvant therapy for gastric cancer: current evidence and future directions

Andrew D Newton  1 , Jashodeep Datta  1 , Arturo Loaiza-Bonilla  1 , Giorgos C Karakousis  1 , Robert E Roses  1
Affiliations
Review

Neoadjuvant therapy for gastric cancer: current evidence and future directions

Andrew D Newton et al. J Gastrointest Oncol. 2015 Oct.

Abstract

Although surgical resection remains the only potentially curative treatment for gastric cancer (GC), poor long-term outcomes with resection alone compel a multimodality approach to this disease. Multimodality strategies vary widely; while adjuvant approaches are typically favored in Asia and the United States (USA), a growing body of evidence supports neoadjuvant and/or perioperative strategies in locally advanced tumors. Neoadjuvant approaches are particularly attractive given the morbidity associated with surgical management of GC and the substantial risk of omission of adjuvant therapy. The specific advantages of chemoradiotherapy (CRT) compared to chemotherapy have not been well defined, particularly in the preoperative setting and trials aimed at determining the optimal elements and sequencing of therapy are underway. Future studies will also define the role of targeted and biologic therapies.

Keywords: Gastric cancer (GC); chemoradiotherapy (CRT); chemotherapy; multimodality therapy; neoadjuvant therapy; radiotherapy; surgery.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to declare.

Figures

Figure 1
Figure 1
Proposed treatment algorithm for a multimodality approach to gastric cancer. EUS, Endoscopic ultrasound.
See this image and copyright information in PMC

References

    1. Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015;136:E359-86. - PubMed
    1. Siegel R, Ma J, Zou Z, et al. Cancer statistics, 2014. CA Cancer J Clin 2014;64:9-29. - PubMed
    1. Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol 2001;2:533-43. - PubMed
    1. Sakuramoto S, Sasako M, Yamaguchi T, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 2007;357:1810-20. - PubMed
    1. Sasako M, Sakuramoto S, Katai H, et al. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol 2011;29:4387-93. - PubMed